Cassava Sciences Announces Completion of an Interim Safety Review of Oral Simufilam On-going Phase 3 Trials
Recently Evaluated the Interim Patient Safety Database for Oral Simufilam in On-going Phase 3 Trials.The DSMB Recommended ...
Cassava Sciences Unusual Options Activity
Today, Benzinga 's options scanner spotted 15 uncommon options trades for Cassava Sciences. This isn't normal. The overall ...
Finanznachrichten4d
Cassava Sciences, Inc.: Cassava Sciences Resolves SEC Investigation
26, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. ("Cassava" or the "Company ... in our Annual Report on Form 10-K for the year ended December 31, 2023, in our Quarterly Report on Form ...
Business Insider7d
Cassava Sciences Announces Completion of an Interim Safety Review of Oral Simufilam On-going Phase 3 Trials
AUSTIN, Texas, Sept. 24, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company focused on Alzheimer’s disease, today announced the completion of a third interim ...
Business Insider4d
Cassava Sciences Resolves SEC Investigation
26, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (“Cassava” or the “Company ... Annual Report on Form 10-K for the year ended December 31, 2023, in our Quarterly Report on Form ...